Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016

Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 data

Published:2024-02-29 Issue:1 Volume:17 Page:
ISSN:2052-3211
Container-title:Journal of Pharmaceutical Policy and Practice
language:en
Short-container-title:Journal of Pharmaceutical Policy and Practice

Author:

Qureshi Omar¹^ORCID,Ramachandran Reshma²³^ORCID,Ross Joseph S.²³⁴^ORCID

Affiliation:

1. Yale School of Medicine, New Haven, CT, USA

2. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

3. Yale Collaboration for Regulatory Rigor, Integrity and Transparency (CRRIT), Yale School of Medicine, New Haven, CT, USA

4. Department of Health Policy and Management, Yale School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, CT, USA

Funder

Yale University

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20523211.2024.2312374

Reference15 articles.

1. Assistant Secretary for Planning and Evaluation – Office of Health Policy. (2023). —Inflation Reduction Act research series— medicare enrollees’ use and out-of-pocket expenditures for drugs selected for negotiation under the Medicare Drug Price Negotiation Program. U.S. Department of Health and Human Services. Retrieved October 23, 2023, from https://aspe.hhs.gov/sites/default/files/documents/9a34d00483a47aee03703bfc565ffee9/ASPE-IRA-Drug-Negotiation-Fact-Sheet-9-13-2023.pdf

2. Cubanski, J. (2023). FAQs about the Inflation Reduction Act’s Medicare drug price negotiation program. Kaiser Family Foundation. Retrieved October 23, 2023, from https://www.kff.org/medicare/issue-brief/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program/

3. Drugs likely subject to Medicare negotiation, 2026-2028

4. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations

5. IQVIA. (2020). Monitoring the impact of COVID-19 on the pharmaceutical market. Retrieved October 31, 2023, from https://www.iqvia.com/-/media/iqvia/pdfs/nordics/covid-reports/nordic_covid-19_cross-country-report-may-2021.pdf